

ACE-HSA PRIORITY TRACK

Supporting faster patient access to health technologies through closer regulatory-health technology assessment (HTA) coordination



What is the ACE-HSA Priority Track?

The Agency for Care Effectiveness (ACE) – Health Sciences Authority (HSA) Priority Track is a joint initiative that aims to support more timely patient access to selected high-impact health technologies. It currently applies to therapeutic drugs and cell, tissue and gene therapy products (CTGTPs).

- ▶ Earlier information sharing between HSA and ACE, with companies' consent
- ▶ Coordinated stakeholder engagement
- ▶ Closer alignment of regulatory review timelines

For selected products, regulatory review and HTA evaluation can proceed concurrently rather than sequentially, helping to shorten the time between regulatory approval and the first HTA decision.

TODAY

Companies typically wait a year or more for the first HTA decision after regulatory approval.

PRIORITY TRACK

This wait can be shortened by **25%–50%**, to about **6–9 months** for companies that come on board via ACE's Company-Led Submission (CLS) process.

Supported by EDB's efforts to engage companies with innovative and impactful technologies, the Priority Track will also help to strengthen Singapore's biomedical ecosystem.

How are health technologies selected for the Priority Track?

Priority considerations



Significant innovation

Demonstrate significant innovation in addressing unmet clinical needs



Cost-effectiveness and value

Meet HTA evidential standards for cost-effectiveness and deliver strong value to the healthcare system



Singapore's health or disease priorities

Aligned with Singapore's health or disease priorities



Commercialisation

Show clear intent to commercialise in Singapore


Additional consideration



Economic value-add

Companies or products that can generate clear economic value-add to Singapore

How the ACE-HSA Priority Track works *Illustrative process flow*



Actual timelines may vary depending on factors including company readiness, submission timelines and the applicable regulatory and HTA processes.

What remains unchanged?



Processes and standards

Regulatory and HTA assessments continue to follow their respective processes and standards, with evidentiary or assessment requirements maintained.



Independent decisions

Regulatory and HTA decisions remain independent.



Regulatory, HTA and funding decisions

Participation does not determine the outcome of any regulatory, HTA or funding decision.

Find out more



To learn more, visit
go.gov.sg/ace-hsa-priority-track



For enquiries,
please contact
ace@moh.gov.sg

Supported by



MINISTRY OF HEALTH
SINGAPORE